New data shows Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy in weight loss, with 65% vs 40% of patients achieving ...

Pres­i­dent Don­ald Trump said he’ll take ex­ec­u­tive ac­tion to have the US pay no more than oth­er coun­tries for drugs, a ...

Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Corvus Pharmaceuticals reported new Phase 1 data in atopic dermatitis that sent its stock price up by as much as 35% premarket Friday.

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

Takeda revealed a handful of pipeline cuts in its fourth-quarter earnings results on Thursday, as the company focuses its attention on six late-stage programs it says could deliver billions of dollars ...